KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EPS (Weighted Average and Diluted): 2012-2024

Historic EPS (Weighted Average and Diluted) for Xenon Pharmaceuticals (XENE) over the last 12 years, with Dec 2024 value amounting to -$3.01.

  • Xenon Pharmaceuticals' EPS (Weighted Average and Diluted) fell 41.98% to -$1.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.89, marking a year-over-year decrease of 37.94%. This contributed to the annual value of -$3.01 for FY2024, which is 10.26% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported EPS (Weighted Average and Diluted) of -$3.01 as of FY2024, which was down 10.26% from -$2.73 recorded in FY2023.
  • Xenon Pharmaceuticals' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.81 during FY2020, with a 5-year trough of -$3.01 in FY2024.
  • In the last 3 years, Xenon Pharmaceuticals' EPS (Weighted Average and Diluted) had a median value of -$2.73 in 2023 and averaged -$2.60.
  • Data for Xenon Pharmaceuticals' EPS (Weighted Average and Diluted) shows a maximum YoY crashed of 118.52% (in 2021) over the last 5 years.
  • Xenon Pharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at -$0.81 in 2020, then crashed by 118.52% to -$1.77 in 2021, then decreased by 16.38% to -$2.06 in 2022, then slumped by 32.52% to -$2.73 in 2023, then decreased by 10.26% to -$3.01 in 2024.